Expertise in
70
conditions

Dr. Stephanie L. Elkins

State Of Mississippi - University Of Mississippi Medical Center
Jackson, MS
Expertise in
70
conditions
Specialties:Hematology | Oncology
Accepting New Patients
Offers Telehealth
Expertise in
70
conditions
OverviewInsuranceLocationsClinical Research

Overview

Stephanie Elkins is a Hematologist and an Oncologist in Jackson, Mississippi. Dr. Elkins is highly rated in 70 conditions, according to our data. Her top areas of expertise are Multiple Myeloma, Polycythemia Vera, Acute Promyelocytic Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Elkins is currently accepting new patients.

Her clinical research consists of co-authoring 6 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in MS
Hospital Affiliations
University Of Mississippi Med Center
Copiah County Medical Center
University Of Mississippi Medical Center- Grenada
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Humana

Locations

STATE OF MISSISSIPPI - UNIVERSITY OF MISSISSIPPI MEDICAL CENTER
2500 N State St, Jackson, MS 39216
601-898-4404

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 03, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: June 07, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Poor-Risk Acute Myelogenous Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Poor-Risk Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: May 03, 2023
Intervention Type: Drug
Study Drugs: Cytarabine, Idarubicin, Pravastatin
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 6 Less Clinical Trials

6 Total Publications

Perspectives on the quality and utility of letters conforming to the AAIM guidelines.
Perspectives on the quality and utility of letters conforming to the AAIM guidelines.
Journal: Journal of community hospital internal medicine perspectives
Published: April 23, 2021
Similar Doctors
Expertise in
72
conditions
Dr. Tammy H. Young
Oncology | Hematology
Expertise in
72
conditions
Dr. Tammy H. Young
Oncology | Hematology

Jackson Oncology Associates

1227 N State St, Suite 101, 
Jackson, MS 
 (1.2 mi)
601-355-2485
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tammy Young is an Oncologist and a Hematologist in Jackson, Mississippi. Dr. Young is highly rated in 72 conditions, according to our data. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Advanced Bronchoscopy. Dr. Young is currently accepting new patients.

Expertise in
46
conditions
Dr. Nicole D. Cleveland
Oncology | Hematology
Expertise in
46
conditions
Dr. Nicole D. Cleveland
Oncology | Hematology

Jackson Oncology Associates

2969 Curran Dr N, Suite 200, 
Jackson, MS 
 (0.5 mi)
601-974-5600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nicole Cleveland is an Oncologist and a Hematologist in Jackson, Mississippi. Dr. Cleveland is highly rated in 46 conditions, according to our data. Her top areas of expertise are Familial Colorectal Cancer, RUNX1 Familial Platelet Disorder, Hemangioma Thrombocytopenia Syndrome, Colorectal Cancer, and Bone Marrow Aspiration. Dr. Cleveland is currently accepting new patients.

Expertise in
62
conditions
Dr. Carolyn L. Bigelow
Hematology | Oncology
Expertise in
62
conditions
Dr. Carolyn L. Bigelow
Hematology | Oncology

State Of Mississippi - University Of Mississippi Medical Center

2500 N State St, 
Jackson, MS 
601-984-6441
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Carolyn Bigelow is a Hematologist and an Oncologist in Jackson, Mississippi. Dr. Bigelow is highly rated in 62 conditions, according to our data. Her top areas of expertise are Multiple Myeloma, Thalassemia, Hemophagocytic Lymphohistiocytosis, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Bigelow is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile